Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
CA 2504665 C · Owner: Panasci, Lawrence Carl · Inventors: Panasci, Lawrence Carl; Aloyz, Raquel Silvia
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a combination which comprises (a) a nitrogen mustard analogue selected from chlorambucil, chlornaphazine estramustine, mechlorethamine, mechlorethamine oxide hydrochloride navembichin, phenestrine, prednimustine trofosfamide or uracil mustard and (b) 4-(4methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4pyridin-3-yl)pyrimidin-2ylamino)phenylJ-benzamide of formula (I) or a pharmaceutically acceptable salt thereof, the invention pertains to the use of said combination for the treatment chronic lymphocytic leukemia.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 10, 2003 and granted December 18, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 10, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 10, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.